Dr. Steven Glanz, MD
Dermatologist
Dr. Steven Glanz is a board-certified dermatologist and the principal investigator for NuLine's dermatology program. He leads clinical trials in atopic dermatitis, psoriasis, chronic urticaria, and acne.
We are a leading provider of clinical trial services for various types of trials.
Our mission is to conduct safe, ethical, and innovative clinical trials that help improve patient outcomes. With a team of experienced professionals and state-of-the-art technology, NuLine Clinical Trial Center is dedicated to bringing new treatments to market faster and more effectively.
We have a proven track record of successfully conducting clinical trials and a commitment to providing high-quality results. Our diverse patient population, bilingual staff, and physician-led operations make us a trusted partner for sponsors seeking efficient, representative enrollment.
NuLine Clinical Trial Center is equipped to support Phase I through Phase IV clinical research. Whether you are evaluating first-in-human safety or conducting post-market surveillance, our site has the infrastructure, the investigators, and the patient population to deliver.
Phase I trials are the first step in testing a new treatment in humans. These small studies typically enroll 20 to 100 participants and focus on evaluating safety, determining safe dosage ranges, and identifying side effects. NuLine's experienced investigators and close monitoring protocols make us a capable site for first-in-human research.
Phase II trials expand testing to larger groups - typically 100 to 300 participants - to assess whether the treatment is effective for its intended condition and to continue evaluating safety. NuLine's diverse patient population gives sponsors access to the broad enrollment needed to generate meaningful efficacy data.
Phase III trials are large-scale, pivotal studies that compare the new treatment against the current standard of care. These trials, enrolling hundreds to thousands of participants, provide the evidence required for FDA approval. NuLine's regulatory-ready operations, clean data record, and experienced coordinators make us a reliable Phase III site partner.
Phase IV studies occur after a treatment has received FDA approval. These trials monitor long-term safety and effectiveness in the real-world patient population, identify rare side effects, and may explore new indications. NuLine supports sponsors with ongoing Phase IV commitments by providing consistent follow-up care and accurate, timely reporting.
Every decision at NuLine begins and ends with participant safety. We strictly follow FDA Good Clinical Practice guidelines, and our physicians are available to every participant throughout the duration of their study.
Clean, audit-ready data is not optional - it is the foundation of our reputation. Our coordinators are trained in source document accuracy, protocol adherence, and timely reporting so sponsors can trust every data point we submit.
Joining a clinical trial takes courage. From the first phone call through the final visit, our staff treats every participant with warmth, patience, and genuine respect - because a person is more than a subject number.
There are no surprises at NuLine. Participants know exactly what study they are in, what to expect at every visit, and what their rights are before they sign anything. Sponsors know our procedures, timelines, and reporting standards upfront.
Effective medicine must work for all people. Our extraordinary cultural and demographic diversity makes NuLine an ideal site for sponsors who need broad, representative enrollment - and we work hard to keep that access open.
Our investigators bring decades of combined experience in clinical research, regulatory science, and therapeutic area expertise. We are not a general practice dabbling in research - clinical trials are what we do.
NuLine's investigators are board-certified specialists - not generalists. Each study is led by a physician with direct expertise in the therapeutic area being studied, giving participants the best care and sponsors the most credible data.
Dermatologist
Dr. Steven Glanz is a board-certified dermatologist and the principal investigator for NuLine's dermatology program. He leads clinical trials in atopic dermatitis, psoriasis, chronic urticaria, and acne.
Women's Health
Dr. Michael Fleischer is a research physician at NuLine Clinical Trial Center with extensive experience in women's health research. He is board certified.
Psychiatry
Dr. Ashish Bhatt is a physician specializing in psychiatric and behavioral health research at NuLine.
Internal Medicine
Dr. Arnold DelPilar Jr. is a physician at NuLine with broad clinical research experience focused on helping patients in the South Florida region.
Family Medicine
Dr. Alvaro Ocampo is an experienced physician at NuLine Clinical Trial Center with a focus on renal and internal medicine research.
Psychiatry
Dr. Carl Thomas Ratliff Jr. is a physician at NuLine Clinical Trial Center with a commitment to clinical research excellence. He works alongside the NuLine team to bring effective, well-monitored investigational treatments to participants in Pompano Beach and surrounding South Florida communities.